SG131115A1 - Method of treating ischemia reperfusion injury using adenosine receptor antagonists - Google Patents

Method of treating ischemia reperfusion injury using adenosine receptor antagonists

Info

Publication number
SG131115A1
SG131115A1 SG200701729-6A SG2007017296A SG131115A1 SG 131115 A1 SG131115 A1 SG 131115A1 SG 2007017296 A SG2007017296 A SG 2007017296A SG 131115 A1 SG131115 A1 SG 131115A1
Authority
SG
Singapore
Prior art keywords
receptor antagonists
reperfusion injury
adenosine receptor
ischemia reperfusion
treating ischemia
Prior art date
Application number
SG200701729-6A
Other languages
English (en)
Inventor
J Smits Glenn
Xiaowei Jin
Garrett J Gross
John Auchampach
Original Assignee
Biogen Idec Inc
Mcw Res Found Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Mcw Res Found Inc filed Critical Biogen Idec Inc
Publication of SG131115A1 publication Critical patent/SG131115A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
SG200701729-6A 2002-06-12 2003-06-12 Method of treating ischemia reperfusion injury using adenosine receptor antagonists SG131115A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38868002P 2002-06-12 2002-06-12

Publications (1)

Publication Number Publication Date
SG131115A1 true SG131115A1 (en) 2007-04-26

Family

ID=29736516

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200701729-6A SG131115A1 (en) 2002-06-12 2003-06-12 Method of treating ischemia reperfusion injury using adenosine receptor antagonists

Country Status (18)

Country Link
US (1) US20050203065A1 (fr)
EP (1) EP1513848A4 (fr)
JP (1) JP2005533054A (fr)
CN (1) CN1671716A (fr)
AU (1) AU2003236509A1 (fr)
BR (1) BR0312137A (fr)
CA (1) CA2489179A1 (fr)
EA (1) EA200500005A1 (fr)
IS (1) IS7592A (fr)
MX (1) MXPA04012629A (fr)
NO (1) NO20050149L (fr)
NZ (1) NZ537444A (fr)
PL (1) PL374498A1 (fr)
RS (1) RS107404A (fr)
SG (1) SG131115A1 (fr)
UA (1) UA84404C2 (fr)
WO (1) WO2003105666A2 (fr)
ZA (1) ZA200500254B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002336650B2 (en) 2001-10-25 2008-06-05 Emory University Catheter for modified perfusion
US20070160645A1 (en) * 2001-10-25 2007-07-12 Jakob Vinten-Johansen PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs
JP2008525468A (ja) * 2004-12-22 2008-07-17 エモリー・ユニバーシティ ポストコンディショニング臓器保護作用を増強する治療補助薬
JP2008534453A (ja) * 2005-03-24 2008-08-28 バイエル・ヘルスケア・アクチェンゲゼルシャフト 再灌流傷害および再灌流障害の処置のための置換２−チオ−３，５−ジシアノ−４−フェニル−６−アミノピリジンの使用
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
TWI404537B (zh) * 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
DE102006046410A1 (de) * 2006-09-20 2008-03-27 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von ischämischen Krankheiten
US20100063071A1 (en) * 2008-06-13 2010-03-11 Kiesman William F Therapeutic compositions and related methods of use
AR085942A1 (es) * 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
WO2012141255A1 (fr) * 2011-04-12 2012-10-18 株式会社 資生堂 Agent d'éclaircissement de la peau et inhibiteur de la production de mélanine
CN102274232B (zh) * 2011-06-22 2013-03-27 南京理工大学 腺苷受体a1拮抗剂在制备药物中的应用
WO2013082458A1 (fr) 2011-12-02 2013-06-06 The Regents Of The University Of California Solution de protection de reperfusion et ses utilisations
CN105209447B (zh) * 2013-03-14 2017-11-21 百时美施贵宝公司 双环[2.2.2]酸gpr120调节剂
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
WO1995011681A1 (fr) * 1993-10-29 1995-05-04 Merck & Co., Inc. Antagonistes du recepteur de l'adenosine humaine
US5733916A (en) * 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) * 1998-03-12 2001-10-16 University Of Virginia Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
SI1230243T1 (sl) * 1999-11-12 2009-08-31 Biogen Idec Inc Policikloalkilpurini kot antagonisti adenozinskega receptorja
JP2003513976A (ja) * 1999-11-12 2003-04-15 バイオジェン インコーポレイテッド アデノシンレセプターアンタゴニストおよびこれを作製し使用する方法
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease

Also Published As

Publication number Publication date
IS7592A (is) 2004-12-10
WO2003105666A3 (fr) 2004-09-16
PL374498A1 (en) 2005-10-31
BR0312137A (pt) 2005-04-05
NO20050149D0 (no) 2005-01-11
AU2003236509A1 (en) 2003-12-31
UA84404C2 (ru) 2008-10-27
MXPA04012629A (es) 2005-10-18
JP2005533054A (ja) 2005-11-04
ZA200500254B (en) 2006-04-26
CA2489179A1 (fr) 2003-12-24
NZ537444A (en) 2006-09-29
NO20050149L (no) 2005-03-11
RS107404A (en) 2007-02-05
CN1671716A (zh) 2005-09-21
EP1513848A2 (fr) 2005-03-16
WO2003105666A2 (fr) 2003-12-24
US20050203065A1 (en) 2005-09-15
EA200500005A1 (ru) 2005-06-30
EP1513848A4 (fr) 2005-11-09

Similar Documents

Publication Publication Date Title
NO20050149D0 (no) Fremgangmate ved behandling av iskemisk reperfusjonsskade ved anvendelse av adenosinreseptor-antagonister
IL178365A (en) Selective antagonists of a2a adenosine receptors
IL175759A0 (en) A2b adenosine receptor antagonists
IL161572A0 (en) Adenosine a2a receptor antagonists
HK1063780A1 (en) Adenosine a2a receptor antagonists
HK1079451A1 (en) Use of compounds that are effective as selective opiate receptor modulators
IL152726A0 (en) Adenosine a2a receptor antagonists
EP1545700A4 (fr) Methode de traitement de degats du systeme nerveux central
PT2260850T (pt) Antagonistas do recetor de a2a para utilização no tratamento de distúrbios de movimento
PT1499316E (pt) Derivados de (1-4-piperidinil)benzimidazole úteis como antagonistas de histamina h3
HK1064097A1 (en) Bicyclic Ä1,2,4Ü -triazole adenosine a2a receptor antagonists
HK1107261A1 (en) Method of wound healing using a2b adenosine receptor antagonists
IL164016A0 (en) Azetidine derivatives as ccr-3 receptor antagonists
AU2003249181A8 (en) Methods for treating or preventing ischemic injury
AU2003298839A8 (en) Benzimidazoles and analogs thereof as antivirals
IL165210A0 (en) Bazedoxifene treatment regimens
AU2003251595A8 (en) Enhancing treatment of mdr cancer with adenosine a3 antagonists
IL160538A0 (en) Enhancing treatment of mdr cancer with adenosine a3 antagonists
HK1085926A1 (en) Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis
SI1594520T1 (sl) Uporaba antagonistov bradikinin-B2 receptorja za zdravljenje osteoartroze
AU2003250685A8 (en) Methods of identifying selective beta-1-adrenergic receptor antagonists
PL383615A1 (pl) Arylindenopirydyny i arylindenopirymidyny oraz ich zastosowanie jako antagonistów receptora adenozynowego A2a
TW506312U (en) Structure for receiving device of retractable tool
GB0201258D0 (en) Ground work enabling apparatus
SI1373220T1 (sl) Benzimidazoli za uporabo pri zdravljenju seksualne disfunkcije